You are here

eczema

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

Motley Fool

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Fierce Pharma

Flag link:

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Xconomy

Flag link:

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Fierce Pharma

Flag link:

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Fierce Pharma

Flag link:

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Fierce Pharma

Flag link:

Sanofi Genzyme hit with patent lawsuit over new eczema drug

Sanofi Genzyme hit with patent lawsuit over new eczema drug

Bizjournals.com

Flag link:

Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

Motley Fool

Flag link:

Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes

Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes

Fierce Pharma

Flag link:

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

Yahoo/Reuters

Flag link:

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Yahoo/Reuters

Flag link:

Sanofi, Regeneron Sue Amgen to Avoid Dupixent Patent Claims

Sanofi, Regeneron Sue Amgen to Avoid Dupixent Patent Claims

Investopedia

Flag link:

Sanofi, Regeneron say latest Dupixent eczema drug tests positive

Sanofi, Regeneron say latest Dupixent eczema drug tests positive

Yahoo/Reuters

clinical trials

Flag link:

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

Endpoints

Flag link:

FDA approves Pfizer ointment for chronic itchy skin condition

FDA approves Pfizer ointment for chronic itchy skin condition

Yahoo/Reuters

Flag link:

FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme

FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme

Bizjournals.com

rheumatoid arthritis

Flag link:

Next-generation eczema drugs on pace for 2017 launch

Next-generation eczema drugs on pace for 2017 launch

BioPharma Dive

Flag link:

Pfizer's Big Bet on Eczema With Anacor Acquisition

Pfizer's Big Bet on Eczema With Anacor Acquisition

Investopedia

Flag link:

4 things to know about Pfizer’s $5.2 billion acquisition target, Anacor

4 things to know about Pfizer’s $5.2 billion acquisition target, Anacor

Marketwatch

Flag link:

Pages